The Vdr: Why Your Vitamin D3 Might Not Be Protecting Your Ageing Brain
Quick Read Vitamin D does more than support bones. It acts as a signalling molecule that switches genes on and
We write a new article on supplements every day , all detailed, with citations.
Once a week we send an email containing a list of the last 7 days articles. Please sign up and also feel free to share the articles with friends and family who you think might benefit.
Simon Parrott – Vitacuity Ltd
CoQ10 is a molecule that helps cells produce energy by working inside mitochondria, the power stations of your cells. Research suggests that conditions like ME/CFS, fibromyalgia, and long COVID may share a common problem: broken-down mitochondria that can’t make energy properly and accumulate damage. CoQ10 addresses this directly by supporting energy production and reducing that damage.
A well-designed trial of 207 people with ME/CFS found that CoQ10 combined with NADH improved fatigue and sleep quality over 12 weeks. Smaller studies using CoQ10 with selenium also showed fatigue improvements. However, most evidence comes from combination supplements rather than CoQ10 alone, sample sizes are small, and when researchers pooled fatigue data from controlled trials, the results weren’t statistically significant yet. The mechanistic case is strong, but the clinical proof isn’t complete.
For persistent unexplained fatigue, CoQ10 is a low-risk option worth considering at 200 to 400 mg daily, preferably taken with food containing fat to improve absorption. The evidence suggests combination with NADH or selenium may be more effective. Don’t expect overnight results, but consistent use over 8 to 12 weeks may help. If you take statins, CoQ10 is particularly relevant since statins deplete your body’s natural CoQ10.
Verdict: CoQ10 has solid biological rationale and promising but incomplete evidence for chronic fatigue, making it a reasonable low-risk intervention to try while larger studies are still needed.
What if the exhaustion that doesn’t lift after a night’s sleep, the fatigue that sits bone-deep, that makes a simple walk feel like a marathon, that clouds your thinking and steals your joy, isn’t a mystery at all, but a problem of cellular energy production? And what if one molecule, quietly working inside virtually every cell in your body, holds a meaningful piece of the answer?
CoQ10 (coenzyme Q10) tends to get discussed in the context of heart health or as a footnote in conversations about statins. But a growing body of research is pointing somewhere more interesting: towards its role in the kind of fatigue that doesn’t fit neatly into any box, post-viral fatigue, fibromyalgia, ME/CFS, and even long COVID. These aren’t conditions that respond to rest or willpower. They appear to share something deeper. And CoQ10 sits at the heart of it.
Vitacuity reviewed over 1.77 million research papers and selected the most relevant studies on this topic. Here’s what the evidence actually shows, and what it honestly doesn’t yet tell us.
To understand why CoQ10 matters for fatigue, you need to understand what mitochondria actually do, and what happens when they don’t do it well.
Mitochondria are the power stations of your cells. They take the food you eat and the oxygen you breathe and convert them into ATP, adenosine triphosphate, the only form of energy your body can actually use at the cellular level. CoQ10 is an essential component of this process. It sits within the inner membrane of the mitochondria and acts as an electron shuttle, carrying electrons between the protein complexes that generate ATP [12, 13].
But CoQ10 doesn’t just generate energy. It exists in two forms, an oxidised form (ubiquinone) and a reduced form (ubiquinol), and cycles continuously between them [12]. In its reduced form, ubiquinol is one of the most potent fat-soluble antioxidants in the body, neutralising the free radicals that are generated as a natural byproduct of energy production. When this cycle is disrupted, when CoQ10 levels are low, you get a double problem: less ATP production and more oxidative damage [12, 13].
Now consider what researchers have found in people with ME/CFS, fibromyalgia, and long COVID: measurable mitochondrial dysfunction, elevated oxidative stress, low-grade inflammation, and immune dysregulation, all present simultaneously [1, 6]. These aren’t separate problems. They appear to be interconnected expressions of the same underlying breakdown in cellular energy metabolism.
CoQ10 has a rational role to play in addressing all of them. As a mitochondrial cofactor, it supports ATP production. As an antioxidant, it counteracts oxidative stress. As an anti-inflammatory agent, it can modulate the inflammatory pathways that accompany these conditions [1, 6, 13]. That’s an unusual combination of roles, and it’s why researchers keep returning to it.
One of the most striking findings in recent research isn’t about a single condition, it’s about what multiple conditions have in common.
A 2025 review published in the *International Journal of Molecular Sciences* examined Gulf War Illness, fibromyalgia, ME/CFS, and long COVID side by side [1]. Despite having completely different origins, a toxic exposure, an unknown trigger, a viral infection, these conditions share a remarkable biological overlap: mitochondrial dysfunction, oxidative stress, neuroinflammation, immune dysregulation, neuroendocrine dysfunction, disruption of the gut-brain axis, and even telomere shortening.
The researchers describe these as a group of “low-energy associated disorders.” They aren’t simply conditions where people feel tired. They appear to involve a fundamental impairment in the body’s ability to produce and utilise cellular energy, and this impairment shows up in measurable biological markers across all four conditions [1].
This framing matters. It shifts CoQ10 from being a speculative supplement to being a rationally targeted intervention, one that addresses a shared biological mechanism rather than chasing symptoms.
Evidence grade: Promising, this is a narrative review drawing on multiple lines of evidence, not a single RCT. The mechanistic case is well-constructed; the clinical evidence is still building.
This is one of the more substantive pieces of clinical evidence available.
A randomised, double-blind, placebo-controlled trial, the gold standard of clinical research, gave 207 ME/CFS patients either 200 mg of CoQ10 combined with 20 mg of NADH daily, or a placebo, for 12 weeks [7]. NADH (the reduced form of nicotinamide adenine dinucleotide) works synergistically with CoQ10 in the mitochondrial energy chain.
The trial found meaningful improvements in perceived fatigue, unrefreshing sleep, and health-related quality of life in the CoQ10 + NADH group [7]. With 207 participants over three months, this is a reasonably sized trial for a condition that is notoriously difficult to study.
The important caveat: the combination used was CoQ10 plus NADH, making it impossible to tease apart exactly how much of the benefit came from CoQ10 alone versus NADH. The two compounds work together in the energy chain, which may mean the combination is greater than the sum of its parts, but it does make isolated attribution tricky.
Evidence grade: Promising, one well-designed RCT with a reasonable sample size. Encouraging, but needs replication and ideally a CoQ10-only arm for comparison.
A smaller open-label study gave 27 ME/CFS patients 400 mg of CoQ10 and 200 μg of selenium daily for 8 weeks [8]. After the intervention, patients reported significant improvements in overall fatigue severity, alongside improvements in circulating biomarkers of oxidative stress and inflammation [8].
Selenium matters here because it’s a co-factor for the enzymes that keep CoQ10 cycling between its oxidised and reduced forms. A review of the CoQ10 redox cycle published in 2024 specifically highlights the clinical rationale for CoQ10 and selenium co-supplementation, noting that deficiencies in components of the ubiquinone-ubiquinol redox cycle have real clinical consequences [12]. If CoQ10 can’t efficiently cycle between its two forms, its antioxidant function is impaired regardless of the dose you take.
The limitation here is obvious: 27 patients, no placebo control, open-label design. This means both researchers and participants knew what was being taken, which introduces the possibility of placebo effect influencing self-reported outcomes.
Evidence grade: Early stage, small, unblinded study. Biologically plausible and directionally positive, but this needs a properly controlled trial before we can draw firm conclusions.
A systematic review and meta-analysis published in the *Journal of Clinical Psychopharmacology* in 2026 pooled five RCTs involving 474 participants and examined CoQ10’s effect on depressive symptoms and fatigue [3].
On depression, the findings were clear: CoQ10 supplementation significantly reduced depressive symptoms compared to control (standardised mean difference: -0.68; 95% CI: -1.02 to -0.33; p<0.01) [3]. This held across diverse populations, patients with multiple sclerosis, breast cancer, polycystic ovary syndrome, major depression, and bipolar disorder.
On fatigue specifically, the picture was different. The meta-analysis found no statistically significant benefit for fatigue (SMD: -0.33; 95% CI: -1.38 to 0.72; p=0.54; I²=89%), though this was based on only two trials with very high heterogeneity, meaning the studies were measuring fatigue differently and in very different populations, making meaningful pooling difficult [3].
This is a genuinely important nuance. CoQ10’s effect on depression-related symptoms appears reasonably well-supported across multiple controlled trials. Its effect on fatigue per se, when measured as a standalone outcome in RCTs, is much less clear. The mechanistic rationale is strong; the RCT data for fatigue as a primary outcome is still underpowered and inconsistent.
Evidence grade for depression: Promising to strong, moderate effect size across five RCTs with 474 participants. Evidence grade for fatigue: Conflicted, the mechanism is plausible, individual studies show benefit, but the pooled RCT evidence doesn’t yet reach statistical significance, largely because there are too few well-designed trials measuring it directly.
A 2021 systematic review specifically examined nutraceutical interventions targeting mitochondrial dysfunction in ME/CFS [14]. Across nine intervention studies, six of nine showed improvements in fatigue levels. CoQ10 featured prominently among the interventions reviewed.
The review’s conclusion was cautious but meaningful: there is insufficient evidence to make definitive claims, but the direction of results is consistently positive, and the biological rationale for targeting mitochondria in ME/CFS is increasingly well-supported [14].
A 2014 clinical review similarly highlighted CoQ10 as one of a set of oral supplements, alongside L-carnitine, alpha-lipoic acid, and NADH, that appear to support mitochondrial function and reduce fatigue in chronic disease, with clinical trials supporting their use in combination [15].
Evidence grade: Promising, consistent directional findings across multiple studies, but study quality varies considerably and sample sizes are small. This is an area where the mechanistic case is ahead of the RCT evidence.
A 2024 overview in a peer-reviewed journal specifically examined the link between mitochondrial dysfunction and post-viral fatigue syndrome, encompassing ME/CFS, fibromyalgia, and long COVID [6]. The authors concluded that the accumulating literature identifies a consistent link between mitochondrial dysfunction and low-grade systemic inflammation in all three conditions, and that CoQ10 supplementation represents a rational therapeutic strategy for addressing this [6].
A 2019 paper in *Pharmacological Research* added further context, noting that ME/CFS patients, or at least a meaningful subgroup of them, show a pro-inflammatory state, elevated oxidative and nitrosative stress, disrupted gut mucosal barriers, and mitochondrial dysfunction with dysregulated bioenergetics [11]. CoQ10 was highlighted as one of the most promising therapeutic agents targeting these pathways.
For anyone who has experienced the particular, bewildering exhaustion of post-viral illness, the fatigue that persists weeks or months after the infection has cleared, this research offers something important: a biological explanation, and a biologically rational intervention.
Evidence grade: Promising, strong mechanistic framework, supported by observational data and small clinical trials, but large-scale RCTs specifically in post-viral fatigue populations are still needed.
It’s important to be honest about the significant gaps in this evidence base, because there are real ones.
The BBB question is unresolved. A 2025 review examined whether supplemental CoQ10 can actually cross the blood-brain barrier in human subjects [5]. The answer is genuinely uncertain. Animal studies suggest it can, but human trials targeting neurological conditions like Parkinson’s and Alzheimer’s, where the rationale is similar, have been largely disappointing. Whether CoQ10 reaches the brain in meaningful quantities from oral supplementation in humans remains an open question [5]. For conditions involving neuroinflammation and brain fatigue, this is a significant unknown.
Most fatigue trials use combination supplements. The largest and best-designed ME/CFS trial used CoQ10 plus NADH, not CoQ10 alone [7]. The fibromyalgia study used CoQ10 plus selenium [8]. This makes it genuinely difficult to know how much of the benefit is attributable to CoQ10 specifically. Combination supplementation may well be superior, there’s a logical case for it, but it complicates the attribution of effects.
The meta-analysis found no significant effect on fatigue as a standalone RCT outcome [3]. This matters. The mechanistic rationale is compelling, individual studies show positive results, but when you pool the controlled trial data and look specifically at fatigue as the primary outcome, the evidence doesn’t yet cross the threshold of statistical significance. This could be because the trials are too small and too few, or because fatigue is measured differently across studies, or because CoQ10’s effect is real but modest. We genuinely don’t know yet.
Sample sizes are small throughout. The open-label selenium study had 27 participants [8]. The systematic review found only nine intervention studies worth including [14]. For a condition as common and debilitating as ME/CFS or long COVID, the clinical research base is underpowered.
We don’t have good dose-response data. Studies have used doses ranging from 200 mg to 400 mg of CoQ10 daily. We don’t yet know what the optimal dose is for fatigue-related conditions, whether ubiquinol (the reduced form) is meaningfully superior to ubiquinone at these doses, or how long supplementation needs to continue before meaningful benefits emerge.
Here’s how a sensible, informed person should think about CoQ10 and chronic fatigue.
The mechanistic case is genuinely strong. CoQ10 is not peripheral to energy metabolism, it’s central to it. The biological overlap between ME/CFS, fibromyalgia, post-viral fatigue, and long COVID is increasingly well-characterised, and mitochondrial dysfunction sits at the heart of all of them. CoQ10 directly addresses this mechanism [1, 6, 11].
The clinical evidence is promising but not yet conclusive. The best trial, 207 patients, double-blind, placebo-controlled, 12 weeks, showed meaningful improvements in ME/CFS using CoQ10 plus NADH [7]. A smaller study showed fatigue improvements with CoQ10 plus selenium [8]. Multiple reviews consistently identify CoQ10 as one of the most rationally targeted interventions for these conditions [1, 6, 14, 15]. But the isolated RCT evidence for CoQ10 alone on fatigue isn’t yet definitive [3].
What should you actually do?
If you’re dealing with persistent fatigue, post-viral, unexplained, or associated with conditions like fibromyalgia, CoQ10 is a reasonable, low-risk intervention to consider. It has an excellent safety profile, is well-tolerated, and the risk-benefit calculation is favourable. The research consistently clusters around 200–400 mg daily. The evidence for combination with NADH or selenium is biologically logical and trial-supported, even if the evidence base is small.
CoQ10 levels decline naturally with age, this is worth knowing if you’re in your 40s or 50s. You’re not supplementing from a position of excess; you’re potentially restoring a molecule that your body is producing less of than it once did [10, 13].
Take CoQ10 with food, ideally a meal containing some fat. It’s fat-soluble, which means absorption is significantly better when taken with dietary fat [13]. This is a simple, free optimisation that most people miss.
If you’re taking a statin, CoQ10 supplementation deserves serious attention. Statins work by inhibiting the same pathway that produces CoQ10, which means they can meaningfully deplete endogenous CoQ10 levels [13]. This is a separate topic with its own evidence base, but it’s directly relevant here.
The honest summary: if you’re experiencing persistent, unrelenting fatigue that doesn’t respond to rest, CoQ10, particularly in combination with NADH or selenium, is one of the more evidence-supported, mechanistically rational things you could try. It’s safe, increasingly well-researched, and costs far less than many interventions with weaker evidence. Don’t expect a dramatic overnight transformation. Do expect that, with consistent use over 8–12 weeks, it may make a meaningful difference to your energy and wellbeing.
The research isn’t complete. But the direction is clear, the mechanism is sound, and the risk is low. Sometimes that’s enough to act on.
[1] Gulf War Illness, Fibromyalgia, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID Overlap in Common Symptoms and Underlying Biological Mechanisms: Implications for Future Therapeutic Strategies (2025). DOI: 10.3390/ijms26189044 | https://pubmed.ncbi.nlm.nih.gov/41009608/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12469932/
[2] A high-dose coenzyme Q emulgel formulation study (2025). DOI: 10.1016/j.xphs.2025.103794 | https://pubmed.ncbi.nlm.nih.gov/40221093/
[3] Effects of Coenzyme Q10 Supplementation on Depressive Symptoms and Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026). DOI: 10.1097/JCP.0000000000002112 | https://pubmed.ncbi.nlm.nih.gov/41294251/
[4] Creatine and post-viral fatigue syndrome: an update (2025). DOI: 10.1080/15502783.2025.2517278 | https://pubmed.ncbi.nlm.nih.gov/40481620/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147496/
[5] Coenzyme Q10 and the Blood-Brain Barrier: An Overview (2025). https://pubmed.ncbi.nlm.nih.gov/40283578/
[6] Mitochondrial Dysfunction and Coenzyme Q10 Supplementation in Post-Viral Fatigue Syndrome: An Overview (2024). https://pubmed.ncbi.nlm.nih.gov/38203745/
[7] Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. DOI: 10.3390/nu13082658 | https://pubmed.ncbi.nlm.nih.gov/34444817/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399248/
[8] Does Coenzyme Q10 Plus Selenium Supplementation Ameliorate Clinical Outcomes by Modulating Oxidative Stress and Inflammation in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? DOI: 10.1089/ars.2022.0018 | https://pubmed.ncbi.nlm.nih.gov/35229657/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057907/
[9] Gulf War Illness, Fibromyalgia, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID Overlap in Common Symptoms and Underlying Biological Mechanisms: Implications for Future Therapeutic Strategies (2025). DOI: 10.3390/ijms26189044 | https://pubmed.ncbi.nlm.nih.gov/41009608/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12469932/
[10] Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases (2023). https://pubmed.ncbi.nlm.nih.gov/37946741/
[11] Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities (2019). DOI: 10.1016/j.phrs.2019.104450 | https://pubmed.ncbi.nlm.nih.gov/31509764/
[12] The Ubiquinone-Ubiquinol Redox Cycle and Its Clinical Consequences: An Overview (2024). https://pubmed.ncbi.nlm.nih.gov/38928470/
[13] Preclinical and Clinical Role of Coenzyme Q10 Supplementation in Various Pathological States (2022). DOI: 10.1055/a-1835-1738 | https://pubmed.ncbi.nlm.nih.gov/35724675/
[14] A systematic review of nutraceutical interventions for mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome (2021). DOI: 10.1186/s12967-021-02742-4 | https://pubmed.ncbi.nlm.nih.gov/33596913/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890871/
[15] Mitochondrial dysfunction and chronic disease: treatment with natural supplements (2014). https://pubmed.ncbi.nlm.nih.gov/24473982/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Vitamin D does more than support bones. It acts as a signalling molecule that switches genes on and
Quick Read Multiple large studies show that people who drink coffee regularly have lower rates of dementia and cognitive decline.
Free guide: The research behind brain health supplements
Plus our weekly research digest — straight to your inbox.
Just leave your email address.